Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390284 · ClinicalTrials.gov registry record · Phase 3
Stop Retinal Ganglion Cell Dysfunction Study
A Phase 3 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT02390284 is a Phase 3 study that was terminated before completion, run by University of Miami. The registered enrollment target is 28 participants.
The verdict
NCT02390284, a Phase 3 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.
Interventions
- DRUG Bimatoprost
- DRUG Latanoprost
- DRUG Dorzolamide
- DRUG Timolol
- DRUG Travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-09 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390284
The ClinicalTrials.gov registry entry for NCT02390284 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bimatoprost is the first listed.
NCT02390284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390284 about?
NCT02390284 is a clinical study titled "Stop Retinal Ganglion Cell Dysfunction Study". Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a populat...
What is the current status of trial NCT02390284?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2015-09. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT02390284?
The interventions under investigation include: Bimatoprost (DRUG), Latanoprost (DRUG), Dorzolamide (DRUG), Timolol (DRUG), Travoprost (DRUG).
Who is sponsoring clinical trial NCT02390284?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.